
Release date: 2026-02-10 17:28:49 Article From: Lucius Laos Recommended: 9
Selumetinib is used to treat type 1 neurofibromatosis (NF1) in pediatric patients aged 2 years and older who have symptomatic, inoperable plexiform neurofibromas (an orphan drug designation granted by the U.S. FDA).
Selumetinib may cause diarrhea, vomiting, nausea, and mouth ulcers. Diarrhea caused by this drug can be severe.
Tell your healthcare provider immediately if you have diarrhea for the first time during treatment. Your healthcare provider may prescribe anti-diarrheal medicine and advise you to drink more fluids.
Selumetinib may cause severe rash.
Tell your healthcare provider if you have any of the following signs of skin problems:
widespread rash, macules, raised skin papules, acne-like rash, blisters, peeling skin, itchy rash, thinning hair or hair loss.
Selumetinib may cause severe muscle problems.
Treatment may increase blood levels of creatine phosphokinase (CPK), which can be a sign of muscle damage.
Increased CPK levels are common during treatment and can also be severe.
Your healthcare provider will perform blood tests to check CPK levels before you start taking Selumetinib and during treatment.
Tell your healthcare provider immediately if you have any of the following symptoms:
muscle aches or pain, muscle spasms and weakness, urine that is dark red or the color of soy sauce.
If any of the above side effects occur, your healthcare provider may adjust your dose, temporarily stop treatment, or permanently discontinue Koselugo.
Avoid eating the following during treatment:
1. St. John’s Wort.
2. Grapefruit or grapefruit juice.
3. Seville oranges.
Before taking the Lucius Pharmaceuticals version of Selumetinib, tell your doctor / pharmacist:
1. If you are allergic to this product, its ingredients, or other medicines, foods, or substances, and what the allergic symptoms are.
2. All prescription and non-prescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to adjust your dose or monitor you closely for side effects.
3. The following products may interact with Selumetinib: St. John’s Wort (Hypericum perforatum), vitamin E. Always tell your doctor before starting treatment and consult a healthcare provider before use.
4. If you have or have had vision problems, difficulty swallowing, heart disease, or liver disease.
5. If you are pregnant, planning to become pregnant, or planning to father a child.
6. You or your partner must use effective contraception during treatment and for 1 week after the last dose.
7. If you become pregnant during treatment, seek medical help immediately. This product may harm the fetus.
8. If you are breastfeeding: breastfeeding is not allowed during treatment and for 1 week after the last dose.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1002025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3792024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:872025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1102025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1052025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1192025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1152025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1112025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: